GSK's Vaccine Gains Expanded U.S. Approval for High-Risk Adults

GSK's vaccine, designed to protect against a severe respiratory virus, has received expanded approval in the United States to include all high-risk adults. Bloomberg posted on X, highlighting the significance of this development in enhancing public health measures. The vaccine, initially approved for a narrower demographic, now aims to provide broader protection against the virus, which poses a significant threat to vulnerable populations. This expansion is expected to improve preventive healthcare strategies and reduce the incidence of respiratory illnesses among high-risk groups.